Heather Marie Froggatt

Heather Marie Froggatt

Auto-generated profile, based on publicly available information

Heather Marie Froggatt

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Science
Verified
Journal Article
Open access
PDF file
NDNir Drayman
Nir Drayman
JDJennifer K. DeMarco
Jennifer K. DeMarco
KJKrysten A. Jones
Krysten A. Jones
SASaara-Anne Azizi
Saara-Anne Azizi
HFHeather M. Froggatt
Heather M. Froggatt
STSavas Tay
Savas Tay
Targeting the main protease of SARS-CoV-2: Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV

13 July 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
HFHeather M. Froggatt
Heather M. Froggatt
AHAlfred Theodore Harding
Alfred Theodore Harding
RCRyan R. Chaparian
Ryan R. Chaparian
NHNicholas Heaton
Nicholas Heaton
The interferon-stimulated transcription factor ETV7 suppresses the type I interferon response.

21 May 2026 in Science
Verified
Journal Article
Closed access
HZHaibo Zhang
Haibo Zhang
KFKatharine Floyd
Katharine Floyd
ZFZhuoqing Fang
Zhuoqing Fang
FHFilipe Araujo Hoffmann
Filipe Araujo Hoffmann
ALAudrey Lee
Audrey Lee
BPBali Pulendran
Bali Pulendran
Traditional vaccines target specific pathogens, limiting their scope against diverse respiratory threats. We describe an intranasal liposomal formulation combining toll-like receptor 4 and 7/8 ligands with a model antigen, ovalbumin, which provided broad, durable protection in mice for at least 3 months against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Staphylococcus aureus . In addition, the vaccine protected mice from other viruses (SARS-CoV-2, SARS, SHC014 coronavirus), bacteria ( Acinetobacter baumannii ), and allergens. Protection was mediated by persistent ovalbumin-specific CD4 + and CD8 + memory T cells that imprinted alveolar macrophages (AMs), enhancing antigen presentation and antiviral immunity. Following infection, vaccinated mice mounted rapid pathogen-specific T cell and antibody responses and formed ectopic lymphoid structures in the lung. These results reveal a class of “universal vaccines” against diverse respiratory threats.